BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
OSENVELT (denosumab-bmwo) by Celltrion is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2025.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OSENVELT (denosumab-bmwo) is a monoclonal antibody biosimilar that blocks RANK ligand to inhibit osteoclast activation and bone resorption. It is indicated for osteoporosis and bone metastasis prevention in patients requiring RANK ligand inhibition. The drug works by binding RANK ligand, preventing osteoclast maturation and survival.
Growth
Early-stage growth phase with emerging commercial opportunity in a crowded biosimilar space; field teams expanding to capture market share from established competitors.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Celltrion is hiring 1 role related to this product
Worked on OSENVELT at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.